ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

BioNTech to produce vaccine in Singapore, as it expands in Asia

Production to start in 2023 in meet regional demand in case of future pandemics

BioNTech is starting to expand its footprint in Asia, spurred on by the COVID-19 pandemic.    © Reuters

SINGAPORE -- German pharmaceutical company BioNTech plans to set up a vaccine manufacturing facility in Singapore as early as 2023 to meet future demand in Southeast Asia, the company announced Monday.

BioNTech will invest "hundreds of millions of U.S. dollars" in the new facility, which it said would produce a range of messenger-RNA vaccines and therapeutics for infectious diseases as well as cancer. Company CEO Ugur Sahin did not specify during a press briefing that the Singapore facility will be used to produce COVID-19 vaccines.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more